Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64436 | 0.86 | ALDH1A1 (0.63) | ALDH1A1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL28166558 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL619004 | 0.82 | LMNA (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19LOX | |
| SCHEMBL28051 | 0.81 | PSIP1 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19MMP13 | |
| SCHEMBL28932041 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19LOX | |
| SCHEMBL5664985 | 0.79 | HTR6 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19LOX | |
| SCHEMBL28865930 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19LOX | |
| SCHEMBL82994 | 0.78 | CA1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MMP13 | |
| SCHEMBL453331 | 0.78 | MMP1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL8605094 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C9CYP2C19ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563847-B1 | MCR DENDRIMERS | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-8865863-B2 | MCR dendrimers | Leibniz-Institut fur Pflandzenbiochemie (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130203960-A1 | MCR DENDRIMERS | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2563847-A1 | MCR DENDRIMERS | Leibniz-Institut für Pflanzenbiochemie (IPB) (DE) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134607-A1 | MCR DENDRIMERS | LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE (DE) | 2011-11-03 | — | — | WO | disclosed |
| EP-1546186-A4 | METHOD FOR SYNTHESIZING PEPTIDES | A & PEP INC (KR) | 2006-02-08 | — | — | EP | disclosed |
| EP-1546186-A1 | METHOD FOR SYNTHESIZING PEPTIDES | A & Pep Inc. (KR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004018501-A1 | METHOD FOR SYNTHESIZING PEPTIDES | A & PEP INC. (KR) | 2004-03-04 | — | — | WO | disclosed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5576419-A | Mild solid-phase synthesis of aligned branched triple-helical peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0693081-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | Novartis AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994024153-A1 | CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203960-A1 | MCR DENDRIMERS | MCRS1, APC, GRPR | ALDH1A1 4194/4885CYP3A4 1961/4885CYP2C9 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.